- About Us
- Customized Drug Release
- Bioavailability Enhancement
- Products for Out-Licensing
- Events & Publications
Please visit our corporate website at www.aptalispharma.com to see a listing of our global locations.
On February 14, 2011, Axcan and Eurand began joint operations and created Aptalis, a specialty pharmaceutical company committed to meeting the needs of patients and physicians with a broad range of GI treatment options.
Our corporate mission is to improve the quality of care and health of patients suffering from diseases including GI disorders and our vision is to serve as the specialty pharma provider of innovative, effective therapies, including GI, around the world.
The Aptalis Pharmaceutical Technologies business specializes in product development that leverages our proprietary pharmaceutical technologies.
We utilize these technologies to develop novel prescription and OTC products with our partners that are designed to have advantages over existing products and address unmet medical needs.
We continue to work with partners to develop and supply our licensed and manufactured products. Integrated R&D and manufacturing teams in the U.S. and Europe support projects from formulation through scale-up and commercial-scale manufacturing.
Our track record of commercialization success includes products that are marketed in more than 50 countries around the world by our partners.